Nalaganje...
埃克替尼在晚期非小细胞肺癌EGFR状态明确的患者中的疗效分析
BACKGROUND AND OBJECTIVE: As the first epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in China, icotinib shows promising anticancer activity in vitro and vivo. The phase Ⅲ clinical study (ICOGEN) showed that icotinib has a good efficacy and tolerability in Chinese patients wit...
Shranjeno v:
| izdano v: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
中国肺癌杂志编辑部
2013
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6015128/ https://ncbi.nlm.nih.gov/pubmed/23514942 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2013.03.04 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|